PRX 003

Drug Profile

PRX 003

Alternative Names: PRX003

Latest Information Update: 03 Oct 2016

Price : $50

At a glance

  • Originator Neotope Biosciences; Onclave Therapeutics
  • Developer Prothena Corporation
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Psoriasis
  • Preclinical Inflammation
  • No development reported Cancer

Most Recent Events

  • 29 Sep 2016 Prothena Corporation plans a phase II trial for Psoriatic arthritis in USA
  • 09 Jun 2016 Interim pharmacodynamics and adverse event data from a phase I trial in Psoriasis (In Volunteers) released by Prothena Biosciences
  • 04 Mar 2016 Interim adverse events and Pharmacodynamics data from a preclinical trial in Inflammation presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and immunology (AAAAI-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top